Nitta Gelatin India Ltd (NGIL), a joint venture between Kerala State Industrial Development Corporation and Nitta Gelatin Inc of Japan has plans to launch new products before the end of financial year 2011-12.
Abbott, India’s leading pharmaceuticals company, has been awarded the Multinational Corporation (MNC) Pharmaceutical Company of the Year award for 2010-2011 at the Frost & Sullivan India Healthcare Excellence Awards held in Mumbai.
Bristol-Myers Squibb Company has announced results from a Phase II clinical trial of 48 treatment-naive genotype 1 hepatitis C infected patients in which treatment with BMS-790052, an NS5A replication complex inhibitor, in combination with peginterferon alfa and ribavirin (pegIFNalfa/RBV) maintained undetectable viral load at 24 weeks post-treatment (SVR24) in 83% (60 mg), 83% (10 mg) and 42% (3 mg) of patients, compared with 25% of patients in the pegIFNalfa/RBV control group after 48 weeks of combination
Inordinate delay in drug approvals and lack of clarity in clinical trial regulations are hurting the pharmaceutical and bio-technology sectors and many of the leading drug makers in India are planning to shift their testing labs outside India.
The integration of Fortis Healthcare (India) with Fortis Healthcare International, a Singapore-based leading healthcare delivery company with presence in nine countries including Hong Kong, Australia, New Zealand, Singapore, Sri Lanka, Dubai Vietnam, Mauritius and Canada, will form one of the largest healthcare delivery networks in the Asia Pacific region.
The Biotechnology Industry Organization (BIO) has announced the program for the Bio Indian International Conference to be held on September 21 – 22, 2011 at the Hyderabad International Convention Centre in Hyderabad. This exclusive forum will bring together biotechnology and pharmaceutical companies from North America, Europe and Asia to meet and explore business opportunities with India’s emerging biotech sector.
The Hyderabad-based Biological E. Limited (BE) has successfully completed the phase 2/3 study in healthy infants between 1 to 3 years in India across eight study sites. This is an important milestone in the clinical development of this vero cell-based inactivated JE vaccine manufactured in India based on the technology transfer agreement with Intercell.
Sun Pharmaceutical Industries said its facility in US has been found to have an "acceptable" regulatory status after the FDA re-inspected it in June.
Organised by Indian Drug Manufacture Association’s Gujarat chapter (IDMA – GSB) in association with Orbitz Exhibitors Pvt. Ltd, the three-day event will be a perfect platform for highlighting the major issues faced by the industry in front of a medical trade oriented and knowledgeable audience.
Herbalife, a global nutrition company, has launched in India six products in three new categories including the Skin Activator Series, Radiant C Series and Fragrances, Ajay Khanna, country head, Herbalife India said in Bangalore.
Reckitt Benckiser, global conglomerate and world leader in household, health and personal care has launched in the Indian market its Power Brand Gaviscon Gaviscon in Tamil Nadu. It is a medicine for heartburn which gives relief from symptoms of heartburn and acidity in just 3 minutes and its effect lasts up to 4 hours. Heartburn is reflux of acid contents (acid, bile and pepsin) into the food pipe which causes a painful burning sensation near the chest area. Gaviscon has a non-systemic mode of action and it does not interfere with body’s digestive process while effectively relieving the symptoms of Heartburn.
Driven by huge domestic demand and increased consumer spending on drugs, India is poised to find its place among the top five global markets for pharmaceutical products by 2020, according to a study.
India’s Planning Commission has proposed to increase the government's expenditure on healthcare by 2-3 percent of the GDP during the 12th Five Year Plan (2012-13 to 2116-17) from the current level of nearly 1 percent.
Leading drug manufacturer Aurobindo Pharma has announced 50/50 joint venture with OJSC Diod, a Russian maker of ecological healthcare equipment and nutrition supplements, to manufacture and market generic (or off-patent) drugs in Russia.
Through 'BIO India International Conference', BIO brings to India more than ten years of experience and expertise in biotech and pharmaceutical partnering.
